An example is PARP1 inhibitors used to treat BRCA2-deficient tumours.36 Since BRCA2 tumours have a deficiency in the DNA repair pathway, they are even more dependent on PARP1 for DNA repair. This evidence concerns the gene PARP1 and neoplasm.